Last update 16 May 2024

Triamcinolone

Last update 16 May 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryTriamcinolone, an exogenous synthetic corticosteroid, functions as a high-affinity agonist of the glucocorticoid receptor (GR), which is predominantly employed in the treatment of autoimmune disorders encompassing psoriasis, lupus, and rheumatoid arthritis, amongst others. The said chemical entity was developed and brought to market by Astellas Pharma, Inc., having secured regulatory approval for therapeutic use as far back as 1996. Depending on the gravity and location of the condition being managed, triamcinolone can be administered in a multitude of formulations, ranging from injectables to topicals and inhalers. Despite its established therapeutic value in the management of a diverse range of autoimmune disorders, the chemical entity has the potential to evoke an array of unwanted effects, including but not limited to mood changes, weight gain, and fluid retention, especially in a subset of the patient population.

Drug Type

Small molecule drug

Synonyms

11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione, 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione

+ [12]

Target

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesRespiratory Diseases

Active Indication

Autoimmune DiseasesAsthmaInfectious Diseases

Inactive Indication

MelanosisRhinitis, Allergic

Originator Organization

Astellas Pharma, Inc.

Active Organization

Tianjin Tianyao Pharmaceuticals Co., Ltd.

Alfresa Pharma Corp.

Inactive Organization

Astellas Pharma US, Inc.Azidus Brasil

Drug Highest PhaseApproved

First Approval Date

US (03 Dec 1957),

Rhinitis, Allergic

Regulation-

Structure

Molecular FormulaC21H27FO6

InChIKeyGFNANZIMVAIWHM-OBYCQNJPSA-N

CAS Registry124-94-7

253

Clinical Trials associated with Triamcinolone

IRCT20240212060964N1 / SuspendedPhase 3IIT

Formulation and standardization of mucoadhesive form of Golnar (Punica granatum L.) and its effectiveness in erythematous and erosive lesions of oral lichen planus and its comparison with mucoadhesive form of triamcinolone: a randomized double-blind clinical trial

Start Date21 May 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

CTRI/2024/04/065942 / Not yet recruitingPhase 3

Comparative study of combination of Intralesional Triamcinolone and radiofrequency ablation versus Intralesional Triamcinolone in the treatment of keloids - NIL

Start Date10 May 2024

Sponsor / Collaborator-

IRCT20150706023081N3 / SuspendedPhase 3

Comparison of the effect of triamcinolone 0.1% topical cream with Timolol 0.5% topical cream in the treatment of patients with hand or foot eczema

Start Date25 Mar 2024

Sponsor / Collaborator

Isfahan University of Medical Sciences

100 Clinical Results associated with Triamcinolone

100 Translational Medicine associated with Triamcinolone

100 Patents (Medical) associated with Triamcinolone

4,579

Literatures (Medical) associated with Triamcinolone

01 May 2024·RETINAL Cases & Brief Reports

SURGICAL DEMONSTRATION OF PRESSURE DIFFERENTIAL THROUGH AN OPTIC DISK PIT

Article

Author: Joseph, Joseph ; Rice, James C ; Scholtz, Raoul P

Purpose:To demonstrate intraoperative dynamic flow through an optic disk pit.Methods:Retrospective interventional case report.Results:Surgical management of an optic disk pit involved standard, 25-gauge, pars plana vitrectomy, induction of posterior hyaloid separation with triamcinolone stain, temporal peripapillary laser, and SF6 gas. Intraoperatively, a remnant of stained vitreous at the optic disk head prolapsed into the optic disk pit with higher intraocular pressure but was drawn back into the vitreous cavity as the intraocular pressure was lowered. This clearly demonstrated a pressure differential across the pit.Conclusion:Communication between the vitreous cavity and the perineural space of the optic nerve is described histologically. Our case demonstrated dynamic flow through the optic disk pit with intraoperative fluctuation of intraocular pressure.

01 May 2024·The Journal of Arthroplasty

Periprosthetic Joint Infection Risk After Primary Total Knee Arthroplasty: Are All Preoperative Corticosteroid Injections the Same?

Article

Author: Guild, George N ; Ayeni, Ayomide M ; Jones, Corey A ; Muffly, Brian T ; Premkumar, Ajay ; Heo, Kevin Y

BACKGROUNDPrevious evidence has demonstrated an increased risk of periprosthetic joint infection (PJI) following primary total knee arthroplasty (TKA) in patients receiving corticosteroid injection (CSI) within 3 months of surgery. The study aimed to determine if PJI risk after TKA varied among different corticosteroid agents.METHODSA total of 85,073 patients undergoing primary TKA from 2009 to 2019 were identified from a large national database. Of these, 1,092 (1.3%) received an ipsilateral, intra-articular CSI within 90 days of TKA. These patients were compared to those not receiving CSI using multivariate logistic regressions following 1:4 propensity score matching, with PJI development as the primary outcome.RESULTSPatients given an injection of any corticosteroid within 90 days of TKA had significantly higher PJI rates compared to controls (1.6 versus 0.41%; P < .001). This finding was driven by patients receiving methylprednisolone acetate (n = 543) or betamethasone (n = 153), with prevalence rates of 1.7 and 2.6%, respectively (P = .003 and P = .01, respectively). No significant increase in the rate of PJI was observed for patients receiving triamcinolone (1.2%; P = .08; n = 342) or dexamethasone (0.0%; P = 1; n = 54) within 90 days preceding TKA. PJI risk for all agents, administered more than 90 days preoperatively normalized to control levels (0.51 versus 0.34%).CONCLUSIONSThese results suggest that PJI risk varies with CSI type. In this large database study, only patients given methylprednisolone acetate or betamethasone injections within 90 days of surgery had significantly higher PJI rates compared to controls.

01 May 2024·Journal of Cosmetic Dermatology

Comparison of the effect of topical triamcinolone 0.1% cream with sulfur 2.0% cream in the treatment of patients with hand eczema: A randomized controlled trial

Article

Author: Asilian, Ali ; Heidaripour, Farzad ; Nateghi, Mohammad Reza ; Mohammadian, Parisa ; Yekta, Amir ; Hosseini, Seyed Mohsen

AbstractBackgroundHand eczema (HE) is a common and heterogeneous condition. It has a wide range of etiologies and clinical manifestations. In this study the efficacy of triamcinolone 0.1% cream and sulfur 2% creams was compared in treating patients with HE.MethodsThis randomized, triple‐blind clinical trial was performed on 70 patients with HE (including 70 right and 70 left hands). In this study, two creams were used including triamcinolone 0.1% and sulfur 2.0%. Patients were treated with these creams twice a day (once in every 12 h) for 4 weeks. Follow‐up was 4 weeks after treatment. Hand Eczema Severity Index (HECSI), itching, dryness, burning sensation, and erythema scores were collected three times during the study and compared between treatment regimens.ResultsFindings showed that both triamcinolone (0.1%) and sulfur (2.0%) creams could significantly reduce the scores of HECSI, itching, dryness, burning sensation, and erythema, and the therapeutic effects lasted for at least 4 weeks after cessation of topical treatment.ConclusionTopical sulfur cream (2.0%) is as effective as triamcinolone (0.1%) cream in treatment of HE without any prominent adverse reactions.

News (Medical) associated with Triamcinolone

29 Feb 2024

·www.fiercepharma.com

After setting out on its own, Sandoz inks $265M deal to resolve 'legacy' price-fixing lawsuit

Direct purchasers from the class action have the right to opt out of the deal, which could reduce the settlement amount by up to 12%, or $31.8 million, Sandoz said Thursday. Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in the past. Sandoz and its subsidiary Fougera Pharmaceuticals have reached a $265 million settlement with direct purchasers for a full release from antitrust allegations in Pennsylvania federal court. The settlement isn’t an admission of wrongdoing, Sandoz explained in a Thursday release. The settlement absolves Sandoz of claims covering alleged conduct between 2009 and 2019, the company said. Individual direct purchasers from the class action have the right to opt out of the deal, which could reduce the settlement amount by up to 12%, or $31.8 million, Sandoz added. With this settlement inked, Sandoz still faces two remaining cases in the multidistrict litigation over alleged price-fixing. Sandoz said it "continues to defend itself vigorously in those cases." Sandoz emerged as a standalone company last October, splitting off from Novartis after more than a year of preparation. Before that Novartis laid out nearly $400 million between 2020 and 2021 to settle similar price-fixing claims against its former generics and biosimilars unit. Back in March of 2020, Novartis agreed to pay $195 million and enter a deferred prosecution agreement to settle federal claims it took part in an industry-wide price-fixing scheme between 2013 and 2015. The settlement came two weeks after a former Sandoz unit executive pleaded guilty to federal conspiracy charges related to the scheme, which allegedly involved drugs like the topical steroid clobetasol and antifungal nystatin triamcinolone cream. Late in 2021, Sandoz inked a related civil deal worth $185 million. The civil portion of the lawsuit related to alleged illegal payments the companies received for the sale of goods at rigged prices. The agreements stemmed from an industrywide price-fixing probe around generic drugs, which also implicated companies such as Teva, Mylan, Lupin and Glenmark.

Patent InfringementAcquisition

12 Oct 2023

·www.prnewswire.com

Arthritis Foundation Announces First-Ever Foundation-Directed Post-Traumatic Osteoarthritis Clinical Trial

The trial studying patients at risk of post-traumatic knee osteoarthritis involves scientists at nine world-class institutions. ATLANTA, Oct. 12, 2023 /PRNewswire/ -- Today, World Arthritis Day, the Arthritis Foundation announced the launch of the first-ever clinical trial directed and sponsored by the Foundation. It will focus on patients at high risk for post-traumatic osteoarthritis (PTOA) in the knee. The Post-Injury Knee Arthritis Severity Outcomes (PIKASO) Trial marks one of the first multi-stakeholder collaborative initiatives of the Arthritis Foundation's Osteoarthritis Clinical Trials Network (OA-CTN), a multi-year, $20 million investment in creating an infrastructure to allow leading research centers to execute randomized clinical trials in osteoarthritis (OA) under a common master protocol. Continue Reading The PIKASO Trial is the first-of-its-kind trial after knee joint injury. To date, there have not been any treatments proven to slow or reverse OA progression, even though OA is a devastating disease and might take decades to fully develop. Until PIKASO, research in developing OA treatments has only involved patients with late-stage OA and significant knee pain. The PIKASO Trial is the first-of-its-kind trial after knee joint injury. Tweet this The five-year PIKASO Trial, a randomized phase II clinical trial, will examine the use of the off-patent drug Metformin in patients with major knee injury who are at high-risk for developing PTOA in the knee after anterior cruciate ligament (ACL) reconstruction. Positive results from this trial would have the potential to enable surgeons to immediately prescribe the drug before a patient undergoes surgery to slow the disease progression, or even fully prevent PTOA. "The PIKASO Trial is the largest science initiative in the Arthritis Foundation's 75-year history," said Steven Taylor, President & CEO of the Arthritis Foundation. "The infrastructure and thought leaders of the OA-CTN allowed us to bring this project to fruition — a complex clinical trial that involves the collaboration of multiple world-class research centers and a stellar interdisciplinary team of scientists." As the first trial sponsored and directed by the Arthritis Foundation, the PIKASO Trial will measure changes in joint structure using advanced imaging techniques and functional improvements using cutting-edge biomechanics measurements. The trial will bring together renowned scientists from the following institutions: Mass General Brigham, the trial's clinical coordinating center Cleveland Clinic, the imaging center that will coordinate the collection and analysis of MRI data University of North Carolina at Chapel Hill, the center that will coordinate the trial's biomechanical and function assessments University of Nebraska Medical Center University of Iowa University of Kentucky The Ohio State University Emory University Hospital for Special Surgery "The launch of the PIKASO Trial is a major milestone in achieving the vision of the OA-CTN, which has been to find promising therapies for OA," said David T. Felson, MD, MPH, professor of medicine and epidemiology at Boston University Chobanian and Avedisian School of Medicine and School of Public Health. "By serving as the convener, the Arthritis Foundation is helping colleagues across the country collaborate like never before to make tangible progress in scientific advancement." The OA-CTN: Filling a Need As a result of expert committee meetings and Arthritis Foundation-funded research, the OA-CTN was formed to share expertise and accelerate cutting-edge research to relieve the burdens of patients at risk for developing OA. In addition to the PIKASO trial, participating centers and trial sites work on a variety of additional research projects intended to advance OA clinical research, such as: The MOCHA Clinical Trial — studying montelukast as a potential chondroprotective treatment following anterior cruciate ligament reconstruction (ACLR) The CoMeT (Corticosteroid Meniscectomy) Clinical Trial — studying whether an injection of long-acting triamcinolone at the time of knee surgery to remove meniscus cartilage can slow or stop OA disease progression The "Biomechanical Changes Following ACL Injury that Influence the Development of Posttraumatic Osteoarthritis" Study — aiming to determine the early time course of relevant biomechanical changes of post-ACLR and association between biomechanics and patient-reported outcomes As the most common form of arthritis, OA affects over 30 million Americans and 500 million people globally. It is also one of the conditions most frequently associated with disability, together with diabetes and dementia, according to a study published in The Lancet Rheumatology. There is also an increased risk of developing OA for those who are obese and have a history of joint injury, and OA is most found in women. Without disease-modifying drugs available, and with a history of little OA clinical trials to lean on, health care providers tend to focus on symptom management and encourage OA patients to increase their level of physical activity. Learn more about how the Arthritis Foundation is leading the way in fueling scientific research and working toward a cure for arthritis: arthritis.org/science. About the Arthritis Foundation The Arthritis Foundation is fighting for all people who live with arthritis. As Champions of Yes, the Arthritis Foundation's mission is to turn the obstacles arthritis causes into opportunities. The Arthritis Foundation champions life-changing solutions and medical advancements, and it also provides ways for people to connect, break down barriers in health care and join the fight to conquer arthritis — uniting hearts, minds and resources to change the future of arthritis. To join the fight to conquer arthritis, visit arthritis.org. CONTACT: Margo Fischgrund 412.414.9960 [email protected] SOURCE The Arthritis Foundation

Phase 2

10 May 2023

·www.biospace.com

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

FarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women. SOUTHLAKE, TX / ACCESSWIRE / May 10, 2023 / FarmaKeio Outsourcing (FKO), a leading pharmaceutical outsourcing facility in the United States, has been granted a patent to produce testosterone and triamcinolone subcutaneous hormone pellets. The patent includes 23 claims, issued by the United States Patent and Trademark Office (USPTO), recognizing the company's innovative approach to compounding hormone therapy and solidifying its position as a leader in the field of pharmaceutical development. The patented hormone pellet formulated with an anti-inflammatory for better outcomes. FarmaKeio Outsourcing's patented pellet is developed in an FDA-registered 503B facility and distinctly designed to deliver a more comfortable treatment option to patients. Unlike other hormone therapies, which may require frequent injections or daily pills, FarmaKeio Outsourcing's hormone pellets provide a sustained release of testosterone and triamcinolone, allowing patients to enjoy the benefits of these hormones for extended periods of time. These pellets are inserted subcutaneously and gradually release the hormone over several months, reducing the need for frequent dosing and allowing patients to focus on their daily lives. "We are thrilled to receive this patent for our subcutaneous hormone pellets," said FarmaKeio Outsourcing's CEO, Dan DeNeui. "Our team has worked tirelessly to develop this innovative approach to hormone therapy, and we are excited to be able to offer this option to patients in need." In addition to providing a more convenient method of hormone therapy, FarmaKeio's pellets offer a unique formulation that is not available from any other FDA 503B registered outsourcing facility in the US. This proprietary formulation has been carefully designed and tested and it represents a significant breakthrough in the field of hormone therapy. "We believe that our hormone pellets have the potential to revolutionize the way that hormone therapy is delivered," said DeNeui. "By offering a sustained release of testosterone and triamcinolone, we can provide patients with a more consistent and reliable treatment option that can improve their quality of life." The issuance of this patent is a significant milestone for FarmaKeio Outsourcing, and it reflects the company's ongoing commitment to innovation and excellence in pharmaceutical development. As the demand for hormone therapy continues to grow, FarmaKeio is well-positioned to meet the needs of patients and healthcare providers alike with its cutting-edge hormone pellets. "We are confident that our hormone pellets will become the gold standard for hormone therapy, and we look forward to working with healthcare providers and patients to make this technology available to as many people as possible," said Chief Operating Officer Cody Boatman. The hormone pellet with triamcinolone is a groundbreaking new product that is set to revolutionize the hormone replacement therapy industry. With its unique combination of hormones and anti-inflammatory properties, it provides patients with a more comfortable treatment option. The pellet is an exclusive feature of The EvexiPEL Method, created and founded by Terri DeNeui, DNP, APRN, ACNP-BC, and is available exclusively through FarmaKeio Outsourcing, an FDA-registered 503B facility. With this new product, FarmaKeio Outsourcing is once again proving its commitment to providing innovative solutions to hormone replacement therapy. About FarmaKeio Outsourcing FarmaKeio Outsourcing is a leading FDA-registered 503B pharmaceutical outsourcing facility that specializes in providing specific custom compounded medications to healthcare providers and facilities across the United States. FarmaKeio Outsourcing is committed to providing innovative, patient-centered solutions that meet the unique needs of their clients. FarmaKeio Outsourcing offers an unwavering commitment to quality, safety, and compliance, operating a state-of-the-art facility that is cGMP compliant and undergoes rigorous testing and quality assurance procedures to ensure the highest level of quality and safety. FarmaKeio Outsourcing provides exceptional customer service and support, ensuring that their clients have access to the resources and expertise necessary to make informed decisions about patient care. FarmaKeio Outsourcing is a trusted partner for healthcare providers looking to offer the most innovative and advanced care solutions to their patients. Contact Information Danielle Tworek Director of Marketing media@farmakeio.com 5613253904 SOURCE: FarmaKeio Outsourcing View source version on accesswire.com:

100 Deals associated with Triamcinolone

External Link

KEGG	Wiki	ATC	Drug Bank
D00385	Triamcinolone	R01AD11 H02AB08 S01BA05 A01AC01 D07AB09 D07XB02 R03BA06 C05AA12	DB00620

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Autoimmune Diseases	CN	Tianjin Tianyao Pharmaceuticals Co., Ltd.	01 Jan 1996
Asthma	JP	Alfresa Pharma Corp.	24 Sep 1958
Infectious Diseases	JP	Alfresa Pharma Corp.	24 Sep 1958

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanosis	Preclinical	BR	Azidus Brasil	01 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2022	Not Applicable	Macular Edema	125	Dexamethasone implants (DEX)	(owkbabdbop) = tghvtwsdpd vhuiofbato (updzmapidf ) View more	-	01 May 2022
				Intravitreal triamcinolone (IVTA)	(owkbabdbop) = tnuwerbijk vhuiofbato (updzmapidf ) View more
ARVO Annual Meeting (ARVO2021)	Not Applicable	Ophthalmologic surgical procedures	46	Intracameral triamcinolone	lkafxabsum(pxvifkzyjb) = epxzzzzhix zngwdsmfvq (xkwemuptta ) View more	Positive	01 Jun 2021
NCT02854995 (Pubmed \| BJU Int)	Not Applicable	-	-	Preputioplasty and intralesional triamcinolone (PIT)	(caztdzfnak) = There was one self-resolving haematoma after PIT gstynuvlru (hheigkshre ) View more	-	01 Dec 2021
ESCRS PREMED study report 6 (Pubmed \| J Cataract Refract Surg)	Not Applicable	Diabetes Mellitus	163	Triamcinolone	ofblueisqh(pkspibuonu) = pvubduduag nwokdopafk (epmgqsoaqy )	-	01 May 2022
				Bevacizumab	ofblueisqh(pkspibuonu) = hmnukvqqzy nwokdopafk (epmgqsoaqy )
AUA2019	Not Applicable	Torticollis	27	Transurethral resection combined with intra- and post-operative triamcinolone injections	(eiugksniim) = gughxbdfpd vagakpxhef (fisrluhkws )	Positive	01 Apr 2019
NCT01175395 (Pubmed \| Br J Ophthalmol) Manual	Phase 1	Choroidal Neovascularization	-	IBI-20089+ranibizumab	(mnohxkrjic) = mild, transient, elevated intraocular pressure in eight patients and cataract progression in three of the five phakic patients fjuwzfdfyu (xqcysxlhbb )	Positive	01 May 2015
NCT00445003 (Pubmed \| Am J Ophthalmol) Manual	Phase 3	Diabetic macular oedema	828	Triamcinolone+laser+Ranibizumab	(fckfbcvwhv) = ixzzflokym mhgcrkjiyu (yyaufwosxz )	Positive	01 Apr 2016
				Triamcinolone+laser	(fckfbcvwhv) = imeldeuiee mhgcrkjiyu (yyaufwosxz )
EULAR2019	Not Applicable	Low Back Pain	582	Dexamethasone	(grxhfkuvqo) = 2.7% of local complications (5 punctures of the thecal sac, 4 extravasations of the contrast and 7 transient pain in lower extremities) heculsszpd (kfcexxpton ) View more	-	12 Jun 2019
				Triamcinolone
PO462 (AAO2019)	Not Applicable	Endophthalmitis	-	Aflibercept	(woigifbgdh) = vdloxyqtnv favcctohan (xduetguawp )	-	12 Oct 2019
				Bevacizumab	(woigifbgdh) = cdrfgqbwxk favcctohan (xduetguawp )
EADV2022	Not Applicable	Keloid	105	Intralesional triamcinolone 4 mg/cm	qiwrnsdpqe(hnpgaqjfzz) = pjgxbwsrym iilziqmopt (trtzzeygvs ) View more	Negative	07 Sep 2022
				Topical pirfenidone 8%	uqlchuqhvg(nndwypzppy) = zbdjvnobtg iaqdohcirh (iwdiguxqnj ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis